Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney drug tested to restart egg growth in early menopause

NCT ID NCT07815509

Symptom relief Sponsor: The University of Hong Kong-Shenzhen Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing whether finerenone, a medicine used for kidney and heart protection, can help women with premature ovarian insufficiency grow ovarian follicles and produce eggs for IVF. About 46 women under 40 with POI will take finerenone or a placebo twice weekly for 24 weeks. The main goal is to see whether more women in the finerenone group have eggs successfully retrieved during an IVF cycle.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
finerenone, a drug used to protect the kidneys and heart
What this could lead to
If it works, finerenone could offer a way to help some women with premature ovarian insufficiency produce eggs for IVF.
What could go wrong
This is a small, early-phase trial of 46 women, so results may not hold up in larger studies. Finerenone can cause high potassium and low blood pressure, and it may not restart egg growth in ovaries that have stopped working.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 46 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 39 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age of women \<40 years. * Diagnosis of POI according to ESHRE 2024 guidelines, defined as: * Oligomenorrhea or amenorrhea for at least 4 months; and * Elevated FSH levels (≥25 mIU/mL) on a single measurement. Exclusion Criteria: * Known hypersensitivity to Finerenone or any of its excipients. * Severe uncontrolled systemic diseases (cardiovascular, hepatic, renal, or endocrine disorders) that may interfere with study participation. * Active malignancy or history of hormone-dependent cancer. * Currently participating in another interventional trial. * Known chromosomal abnormalities or clinically significant genetic syndromes associated with POI.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Premature ovarian insufficiency are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary ovarian failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Premature ovarian insufficiency

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The University of Hong Kong Shenzhen Hospital

    Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.